Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test

Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test

In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by Regeneron Pharmaceuticals and Bayer. The post Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test appeared first on MedCity News.

Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial

Ocular Therapeutix said Tuesday that its experimental treatment, called Axpaxli, maintained vision with less frequent injections compared to a standard treatment for patients with a common cause of age-related blindness — achieving the primary goal of a late-stage clinical trial.  However, the difference in the durability of treatment between Axpaxli and the active control in the study was narrower than investors expected — a finding that may sp…

Ocular Therapeutix Announces Positive Phase 3 SOL-1 Results Demonstrating Superiority of Axpaxli in Wet AMD

Ocular Therapeutix announced positive topline results from its SOL-1 phase 3 superiority trial evaluating Axpaxli (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (AMD). The SOL-1 trial met its primary endpoint with high statistical significance, demonstrating superiority of a single dose of Axpaxli (0.45 mg) compared with a single dose of aflibercept (2 mg) at Week 36. Under the pre-specified statistical analysi…

Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink

Ocular Therapeutix’ investigational drug could become the preferred therapy for wet age-related macular degeneration after data released Tuesday showed statistical superiority to Regeneron and Bayer’s current bestseller Eylea. However, the data from the trial appear ...